Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer

Daniel R. Plaugher; Avery R. Childress; Christian M. Gosser; Dave Preston Esoe; Kassandra J. Naughton; Zhonglin Hao; Christine F. Brainson

doi:10.1016/j.canlet.2024.217281

Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer

Daniel R. Plaugher, Avery R. Childress, Christian M. Gosser, Dave Preston Esoe, Kassandra J. Naughton, Zhonglin Hao, Christine F. Brainson

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Lung cancer is the leading cause of cancer-related death worldwide, with poor outcomes even for those diagnosed at early stages. Current standard-of-care for most non-small cell lung cancer (NSCLC) patients involves an array of chemotherapy, radiotherapy, immunotherapy, targeted therapy, and surgical resection depending on the stage and location of the cancer. While patient outcomes have certainly improved, advances in highly personalized care remain limited. However, there is growing excitement around harnessing the power of tumor-infiltrating lymphocytes (TILs) through the use of adoptive cell transfer (ACT) therapy. These TILs are naturally occurring, may already recognize tumor-specific antigens, and can have direct anti-cancer effect. In this review, we highlight comparisons of various ACTs, including a brief TIL history, show current advances and successes of TIL therapy in NSCLC, discuss the potential roles for epigenetics in T cell expansion, and highlight challenges and future directions of the field to combat NSCLC in a personalized manner.

Original language	English
Article number	217281
Journal	Cancer Letters
Volume	605
DOIs	https://doi.org/10.1016/j.canlet.2024.217281
State	Published - Nov 28 2024

Bibliographical note

Publisher Copyright:
© 2024 Elsevier B.V.

Funding

This work was supported in part by NCI T32 CA165990 (DRP), R01 CA237643, P20 GM121327-03, R01 HL170193, R01 CA266004, P30 CA177558, the American Institute for Cancer Research Grant 710410, and the Markey Women Strong Distinguished Researcher Award 2023 (CFB). Images were created in part by biorender.com. This work was supported in part by NCI T32 CA165990 (DRP), R01 CA237643, P20 GM121327-03, R01 HL170193, R01 CA266004, P30 CA177558, the American Institute for Cancer Research Grant 710410, and the Markey Research Women Strong Distinguished Researcher Award 3048116064 (CFB). Images were created in part by biorender.com .

Funders	Funder number
Markey Foundation Markey Women Strong
National Childhood Cancer Registry – National Cancer Institute	R01 CA266004, P30 CA177558, P20 GM121327-03, T32 CA165990, R01 CA237643, R01 HL170193
National Childhood Cancer Registry – National Cancer Institute
American Institute for Cancer Research	710410
American Institute for Cancer Research
Markey Research Women Strong	3048116064

Keywords

Adoptive cell transfer
Non-small cell lung cancer
Tumor-infiltrating lymphocytes

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.canlet.2024.217281

Cite this

@article{c6742623168e44fb88da61e136361049,

title = "Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer",

abstract = "Lung cancer is the leading cause of cancer-related death worldwide, with poor outcomes even for those diagnosed at early stages. Current standard-of-care for most non-small cell lung cancer (NSCLC) patients involves an array of chemotherapy, radiotherapy, immunotherapy, targeted therapy, and surgical resection depending on the stage and location of the cancer. While patient outcomes have certainly improved, advances in highly personalized care remain limited. However, there is growing excitement around harnessing the power of tumor-infiltrating lymphocytes (TILs) through the use of adoptive cell transfer (ACT) therapy. These TILs are naturally occurring, may already recognize tumor-specific antigens, and can have direct anti-cancer effect. In this review, we highlight comparisons of various ACTs, including a brief TIL history, show current advances and successes of TIL therapy in NSCLC, discuss the potential roles for epigenetics in T cell expansion, and highlight challenges and future directions of the field to combat NSCLC in a personalized manner.",

keywords = "Adoptive cell transfer, Non-small cell lung cancer, Tumor-infiltrating lymphocytes",

author = "Plaugher, \{Daniel R.\} and Childress, \{Avery R.\} and Gosser, \{Christian M.\} and Esoe, \{Dave Preston\} and Naughton, \{Kassandra J.\} and Zhonglin Hao and Brainson, \{Christine F.\}",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier B.V.",

year = "2024",

month = nov,

day = "28",

doi = "10.1016/j.canlet.2024.217281",

language = "English",

volume = "605",

}

TY - JOUR

T1 - Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer

AU - Plaugher, Daniel R.

AU - Childress, Avery R.

AU - Gosser, Christian M.

AU - Esoe, Dave Preston

AU - Naughton, Kassandra J.

AU - Hao, Zhonglin

AU - Brainson, Christine F.

PY - 2024/11/28

Y1 - 2024/11/28

N2 - Lung cancer is the leading cause of cancer-related death worldwide, with poor outcomes even for those diagnosed at early stages. Current standard-of-care for most non-small cell lung cancer (NSCLC) patients involves an array of chemotherapy, radiotherapy, immunotherapy, targeted therapy, and surgical resection depending on the stage and location of the cancer. While patient outcomes have certainly improved, advances in highly personalized care remain limited. However, there is growing excitement around harnessing the power of tumor-infiltrating lymphocytes (TILs) through the use of adoptive cell transfer (ACT) therapy. These TILs are naturally occurring, may already recognize tumor-specific antigens, and can have direct anti-cancer effect. In this review, we highlight comparisons of various ACTs, including a brief TIL history, show current advances and successes of TIL therapy in NSCLC, discuss the potential roles for epigenetics in T cell expansion, and highlight challenges and future directions of the field to combat NSCLC in a personalized manner.

AB - Lung cancer is the leading cause of cancer-related death worldwide, with poor outcomes even for those diagnosed at early stages. Current standard-of-care for most non-small cell lung cancer (NSCLC) patients involves an array of chemotherapy, radiotherapy, immunotherapy, targeted therapy, and surgical resection depending on the stage and location of the cancer. While patient outcomes have certainly improved, advances in highly personalized care remain limited. However, there is growing excitement around harnessing the power of tumor-infiltrating lymphocytes (TILs) through the use of adoptive cell transfer (ACT) therapy. These TILs are naturally occurring, may already recognize tumor-specific antigens, and can have direct anti-cancer effect. In this review, we highlight comparisons of various ACTs, including a brief TIL history, show current advances and successes of TIL therapy in NSCLC, discuss the potential roles for epigenetics in T cell expansion, and highlight challenges and future directions of the field to combat NSCLC in a personalized manner.

KW - Adoptive cell transfer

KW - Non-small cell lung cancer

KW - Tumor-infiltrating lymphocytes

UR - https://www.scopus.com/pages/publications/85205793205

UR - https://www.scopus.com/inward/citedby.url?scp=85205793205&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2024.217281

DO - 10.1016/j.canlet.2024.217281

M3 - Review article

C2 - 39369769

AN - SCOPUS:85205793205

SN - 0304-3835

VL - 605

JO - Cancer Letters

JF - Cancer Letters

M1 - 217281

ER -

Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this